With Jeuveau Approval, Evolus Will Focus On The Beauty Business To Gain Market Share
Evolus believes its focus on the beauty business will be a differentiator for its neurotoxin Jeuveau. The company will publish head-to-head results against Botox alongside the Spring 2019 launch and does not expect a new trade secrets complaint from Botox maker Allergan to delay its product.
You may also be interested in...
The only addition to AbbVie’s leadership after it closes the $63bn acquisition of Allergan will be Carrie Strom, who will lead the Allergan Aesthetics business.
The ongoing battle between Korea's Medytox and Daewoong Pharm over the source of the botulinum toxin strain in Daewoong’s product looks set to rumble on until a trade commission unveils the results of its probe next year.
AbbVie is buying Allergan for its product sales, both to increase its own revenues and to fund future R&D and business development, so Allergan's Q2 gains are good news.